PDF(Pubmed)
Abstract：
UNASSIGNED: Microwave ablation (MWA) for hepatocellular carcinoma (HCC) under the hepatic dome is still clinically challenging. This retrospective control study set out to analyze the technical application and clinical benefits of cone beam computed tomography (CBCT)-guided MWA for HCC under the hepatic dome.
UNASSIGNED: The study analyzed 76 patients with 110 HCC lesions under the hepatic dome from April 2016 to January 2020. The patients were divided into two groups: (I) the CBCT group (n=31), in which iGuide navigation was used for the puncture, and (II) the conventional computed tomography (cCT) group (n=45), in which a navigation tool was not used for the puncture. The primary endpoints were technical success, puncture score, and the rates of complete ablation (CA), complications, and local tumor progression (LTP). The secondary endpoints were tumor-free survival (TFS) and overall survival (OS).
UNASSIGNED: In terms of the primary endpoints, the puncture score, occurrence of pleural effusion, and occurrence of right shoulder pain differed significantly between the CBCT group and the cCT group (2.8 vs. 2.2, P=0.002; 12.9% vs. 35.6%, P=0.03; 9.7% vs. 33.3%, P=0.03, respectively). However, the rates of technical success, CA, major complications, and LTP showed no significant differences between the two groups (100% vs. 100%, P>0.009; 0% vs. 0%, P>0.009; 95.6% vs. 89.2%, P=0.30; 4.5% vs. 4.6%, P=0.96, respectively). Regarding the secondary endpoints, the median TFS was 23.0 [95% confidence interval (CI): 19.5-26.5] vs. 22.0 (95% CI: 18.4-25.6) months (P=0.41) and the median OS was 31.0 (95% CI: 21.4-40.6) vs. 33.0 (95% CI: 27.9-38.2) months (P=0.95).
UNASSIGNED: Cone beam CT is a feasible and effective image guidance tool for MWA of HCC under the hepatic dome.
UNASSIGNED: The study analyzed 76 patients with 110 HCC lesions under the hepatic dome from April 2016 to January 2020. The patients were divided into two groups: (I) the CBCT group (n=31), in which iGuide navigation was used for the puncture, and (II) the conventional computed tomography (cCT) group (n=45), in which a navigation tool was not used for the puncture. The primary endpoints were technical success, puncture score, and the rates of complete ablation (CA), complications, and local tumor progression (LTP). The secondary endpoints were tumor-free survival (TFS) and overall survival (OS).
UNASSIGNED: In terms of the primary endpoints, the puncture score, occurrence of pleural effusion, and occurrence of right shoulder pain differed significantly between the CBCT group and the cCT group (2.8 vs. 2.2, P=0.002; 12.9% vs. 35.6%, P=0.03; 9.7% vs. 33.3%, P=0.03, respectively). However, the rates of technical success, CA, major complications, and LTP showed no significant differences between the two groups (100% vs. 100%, P>0.009; 0% vs. 0%, P>0.009; 95.6% vs. 89.2%, P=0.30; 4.5% vs. 4.6%, P=0.96, respectively). Regarding the secondary endpoints, the median TFS was 23.0 [95% confidence interval (CI): 19.5-26.5] vs. 22.0 (95% CI: 18.4-25.6) months (P=0.41) and the median OS was 31.0 (95% CI: 21.4-40.6) vs. 33.0 (95% CI: 27.9-38.2) months (P=0.95).
UNASSIGNED: Cone beam CT is a feasible and effective image guidance tool for MWA of HCC under the hepatic dome.
摘要：
UASSIGNED：肝穹顶下肝细胞癌（HCC）的微波消融（MWA）在临床上仍然具有挑战性。这项回顾性对照研究旨在分析锥形束计算机断层扫描（CBCT）引导的MWA在肝穹顶下用于HCC的技术应用和临床益处。
UNASSIGNED：该研究分析了2016年4月至2020年1月在肝穹顶下具有110个HCC病变的76例患者。将患者分为两组：（I）CBCT组（n=31），其中iGuide导航用于穿刺，和(II)常规计算机断层扫描(cCT)组(n=45)，其中没有使用导航工具进行穿刺。主要终点是技术成功，穿刺分数,和完全消融率（CA），并发症,和局部肿瘤进展(LTP)。次要终点是无瘤生存期(TFS)和总生存期(OS)。
UNASSIGNED：就主要终点而言，穿刺分数,胸腔积液的发生，CBCT组和cCT组之间右肩疼痛的发生率显着不同（2.8vs.2.2，P=0.002；12.9%vs.35.6%,P=0.03；9.7%vs.33.3%,分别为P=0.03)。然而,技术成功率，CA,主要并发症,和LTP在两组之间没有显着差异（100％vs.100%,P>0.009;0%vs.0%,P>0.009;95.6%vs.89.2%,P=0.30；4.5%vs.4.6%,分别为P=0.96)。关于次要终点，中位TFS为23.0[95%置信区间（CI）：19.5-26.5]。22.0（95％CI：18.4-25.6）个月（P=0.41），中位OS为31.0（95％CI：21.4-40.6）。33.0（95%CI：27.9-38.2）个月（P=0.95）。
UNASSIGNED：锥形束CT是肝穹顶下HCCMWA的可行有效的图像引导工具。
UNASSIGNED：该研究分析了2016年4月至2020年1月在肝穹顶下具有110个HCC病变的76例患者。将患者分为两组：（I）CBCT组（n=31），其中iGuide导航用于穿刺，和(II)常规计算机断层扫描(cCT)组(n=45)，其中没有使用导航工具进行穿刺。主要终点是技术成功，穿刺分数,和完全消融率（CA），并发症,和局部肿瘤进展(LTP)。次要终点是无瘤生存期(TFS)和总生存期(OS)。
UNASSIGNED：就主要终点而言，穿刺分数,胸腔积液的发生，CBCT组和cCT组之间右肩疼痛的发生率显着不同（2.8vs.2.2，P=0.002；12.9%vs.35.6%,P=0.03；9.7%vs.33.3%,分别为P=0.03)。然而,技术成功率，CA,主要并发症,和LTP在两组之间没有显着差异（100％vs.100%,P>0.009;0%vs.0%,P>0.009;95.6%vs.89.2%,P=0.30；4.5%vs.4.6%,分别为P=0.96)。关于次要终点，中位TFS为23.0[95%置信区间（CI）：19.5-26.5]。22.0（95％CI：18.4-25.6）个月（P=0.41），中位OS为31.0（95％CI：21.4-40.6）。33.0（95%CI：27.9-38.2）个月（P=0.95）。
UNASSIGNED：锥形束CT是肝穹顶下HCCMWA的可行有效的图像引导工具。
